UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): July 09, 2021 |
Flexion Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
| | | | |
Delaware | 001-36287 | 26-1388364 |
(State or Other Jurisdiction
of Incorporation) | (Commission File Number) | (IRS Employer
Identification No.) |
| | | | |
10 Mall Road Suite 301 | |
Burlington, Massachusetts | | 01803 |
(Address of Principal Executive Offices) | | (Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: 781 305-7777 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| | | | |
Title of each class
| | Trading
Symbol(s) | |
Name of each exchange on which registered
|
Common Stock, $0.001 par value per share | | FLXN | | Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d) On July 9, 2021, the Board of Directors (the “Board”) of Flexion Therapeutics, Inc. (the “Company”) appointed Mr. Utpal Koppikar as a director of the Company. Mr. Koppikar will serve as a Class II director with an initial term expiring at the Company’s 2022 annual meeting of stockholders, or until his earlier death, resignation, or removal. Mr. Koppikar was also appointed to serve as a member and Chair of the Audit Committee of the Board, replacing Mr. Patrick Mahaffy, who was serving in an interim role as a member and Chair of that Committee.
Mr. Koppikar will receive compensation in accordance with the Company’s Non-Employee Director Compensation Policy previously filed as Exhibit 10.6 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 12, 2020. The Company also entered into a standard form of indemnity agreement with Mr. Koppikar effective upon his appointment to the Board.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | |
| | | Flexion Therapeutics, Inc. |
| | | |
Date: | July 12, 2021 | By: | /s/ Mark S. Levine |
| | | Mark S. Levine
General Counsel & Corporate Secretary |
